Rein Therapeutics, Inc. (RNTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 23, 2025, details the results of the 2025 Annual Meeting of Stockholders for Rein Therapeutics, Inc. The meeting was previously adjourned from June 24, 2025, to finalize voting on specific corporate governance matters.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes rather than financial performance.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Director Election: Stockholders elected William C. Fairey as a Class II director for a three-year term expiring at the 2028 Annual Meeting.
- For: 7,661,847 votes
- Withheld: 1,621,599 votes
- Broker Non-Votes: 0
- Executive Compensation (Say-on-Pay): Stockholders approved, on a non-binding advisory basis, the Company's named executive officer compensation.
- For: 8,325,803 votes
- Against: 146,938 votes
- Abstain: 810,705 votes
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the administrative results of the annual meeting.
Key Facts for Investor Verification
- William C. Fairey was successfully elected to the Board of Directors for a term ending in 2028.
- Stockholders approved the executive compensation plan with approximately 85% of votes cast in favor (excluding abstentions).
- The meeting was an adjourned session originally scheduled for June 24, 2025.
- No financial data or operational updates were disclosed in this specific filing.